Avalo Therapeutics Inc. (AVTX)
NASDAQ: AVTX
· Real-Time Price · USD
3.96
0.10 (2.59%)
At close: May 16, 2025, 3:59 PM
3.91
-1.26%
After-hours: May 16, 2025, 05:49 PM EDT
Avalo Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|
| Product Revenue | 441K | 1.41M | 3.36M | 4.77M | 6.7M |
| Product Revenue Growth | -68.68% | -58.15% | -29.52% | -28.75% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.55M | 5.23M | 4.29M | 4.53M | 3.16M | 2.63M | 2.49M | 2.43M | 2.71M | 2.96M | 3.28M | 2.78M | 11.68M | 5.98M | 5.93M | 7.4M | 5.35M | 4.62M | 5.04M | 6.75M | 3.35M | -4.85M | 5.31M | 5.32M | 5.83M | 5.48M | 4.2M | 5.08M | 4.44M | 3.99M | 2.15M | 1.44M | 1.33M | 1.09M | 1.7M | 1.64M | 2.65M | 1.92M | 721.66K | 1.02M | 760.71K |
| Selling, General, and Administrative Revenue Growth | +5.98% | +22.10% | -5.34% | +43.34% | +19.98% | +5.74% | +2.60% | -10.38% | -8.48% | -9.90% | +17.96% | -76.17% | +95.35% | +0.93% | -19.96% | +38.50% | +15.81% | -8.33% | -25.45% | +101.47% | -169.16% | -191.29% | -0.17% | -8.70% | +6.38% | +30.55% | -17.48% | +14.41% | +11.27% | +85.59% | +49.52% | +8.18% | +21.49% | -35.71% | +4.06% | -38.21% | +37.69% | +166.61% | -28.97% | +33.57% | n/a |
| Research and Development Revenue | 9.12M | 8.18M | 9.54M | 4.6M | 2.12M | 1.87M | 1.25M | 4.66M | 6.01M | 6.17M | 7.04M | 8.51M | 9.58M | 11.51M | 10.55M | 12.57M | 25.21M | 12.64M | 8.87M | 5.92M | 4.77M | 2.91M | 1.74M | 3.71M | 3.4M | 2.01M | 1.05M | 1.08M | 1.65M | 1.96M | 964.57K | 493.65K | 953.07K | 773K | 4.58M | 2.5M | 2.29M | 1.75M | 1.24M | 1.88M | 1.72M |
| Research and Development Revenue Growth | +11.49% | -14.21% | +107.30% | +117.44% | +13.34% | +49.48% | -73.19% | -22.47% | -2.66% | -12.35% | -17.25% | -11.21% | -16.73% | +9.09% | -16.06% | -50.13% | +99.48% | +42.43% | +49.94% | +24.10% | +64.01% | +66.73% | -53.04% | +9.16% | +69.53% | +91.46% | -3.22% | -34.37% | -15.88% | +103.33% | +95.40% | -48.20% | +23.30% | -83.13% | +83.14% | +9.09% | +30.97% | +41.51% | -34.02% | +8.82% | n/a |